Compare Jones Lang LaSalle Inc (JLL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs TG Therapeutics Inc — how do they compare? Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and TG Therapeutics Inc for 16 Days on average.
| JLL | TGTX | |
|---|---|---|
Market Cap | $13.95B | $8.16B |
Volume | 457,462 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $59.06 |
52-Week Low | $280.16 | $26.94 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $16.71B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $303.14, up 2.18% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $26.12B in 2025 and improving profit margins. Analyst consensus remains bullish with a $450.50 price target, though technical indicators suggest near-term caution.
JLL presents a compelling value opportunity with attractive valuation ratios (P/E 14.54, P/S 0.53) and consistent earnings outperformance. Key risks include real estate market cyclicality and competitive pressures, but strong institutional support and strategic acquisitions support long-term growth prospects.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
